Cantargia AB (publ) (STO:CANTA)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.800
-0.625 (-14.12%)
Dec 5, 2025, 5:29 PM CET
107.65%
Market Cap 944.72M
Revenue (ttm) 308.69M
Net Income (ttm) 139.93M
Shares Out 248.61M
EPS (ttm) 0.60
PE Ratio 6.31
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,828,437
Average Volume 4,449,726
Open 3.680
Previous Close 4.425
Day's Range 3.350 - 4.080
52-Week Range 1.000 - 4.775
Beta 1.70
RSI 57.64
Earnings Date Nov 19, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 22
Stock Exchange Nasdaq Stockholm
Ticker Symbol CANTA
Full Company Profile

Financial Performance

Financial Statements

News

Cantargia AB (FRA:7V3) Q3 2025 Earnings Call Highlights: First-Ever Profits and Promising ...

Cantargia AB (FRA:7V3) Q3 2025 Earnings Call Highlights: First-Ever Profits and Promising Cancer Treatment Results

16 days ago - GuruFocus

Q3 2025 Cantargia AB Earnings Call Transcript

Q3 2025 Cantargia AB Earnings Call Transcript

16 days ago - GuruFocus

Cantargia AB (FRA:7V3) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Updates

Cantargia AB (FRA:7V3) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Updates

1 year ago - GuruFocus

Q3 2024 Cantargia AB Earnings Call Transcript

Q3 2024 Cantargia AB Earnings Call Transcript

1 year ago - GuruFocus